Session » Spondylarthropathies and Psoriatic Arthritis – Clinical Aspects and Treatment II: Axial Spondyloarthritis – Treatment
- 4:30PM-6:00PM
-
Abstract Number: 1045
2016 Update of the ASAS-EULAR Management Recommendations for Axial Spondyloarthritis
- 4:30PM-6:00PM
-
Abstract Number: 1041
Abatacept in the Treatment of Active Psoriatic Arthritis: 24-Week Results from a Phase III Study
- 4:30PM-6:00PM
-
Abstract Number: 1046
Anti-TNF Therapy in Axial Spondyloarthritis: Prediction of Therapeutic Responses Using Immunological Signatures
- 4:30PM-6:00PM
-
Abstract Number: 1042
Four Year Imaging Outcomes in Patients with Axial Spondyloarthritis Treated with Certolizumab Pegol, Including Patients with Ankylosing Spondylitis and Non-Radiographic Axial Spondyloarthritis
- 4:30PM-6:00PM
-
Abstract Number: 1043
Safety and Efficacy of Intravenous Golimumab in Adult Patients with Active Ankylosing Spondylitis: Results through Week 28
- 4:30PM-6:00PM
-
Abstract Number: 1044
Treatment with Tofacitinib Is Associated with Clinically Meaningful Reductions in Axial MRI Inflammation in Patients with Ankylosing Spondylitis